



# HHS Public Access

Author manuscript

*Eur J Radiol.* Author manuscript; available in PMC 2021 September 07.

Published in final edited form as:

*Eur J Radiol.* 2020 August ; 129: 109096. doi:10.1016/j.ejrad.2020.109096.

## Renal cell carcinoma: Associations between tumor imaging features and epidemiological risk factors

Andreas M. Hötter<sup>a,\*</sup>, Christoph A. Karlo<sup>b</sup>, Pier Luigi Di Paolo<sup>c</sup>, Junting Zheng<sup>d</sup>, Chaya S. Moskowitz<sup>d</sup>, Paul Russo<sup>e</sup>, Hedvig Hricak<sup>f</sup>, Oguz Akin<sup>f</sup>

<sup>a</sup>University Hospital Zurich, Institute of Diagnostic and Interventional Radiology, Rämistrasse 100, 8091, Zurich, Switzerland

<sup>b</sup>Hirslanden Clinic, Witellikerstrasse 40, 8032, Zurich, Switzerland

<sup>c</sup>Bambino Gesù Children's Hospital, Department of Radiology, Piazza San Onofrio 4, 00165, Rome, Italy

<sup>d</sup>Memorial Sloan-Kettering Cancer Center, Department of Epidemiology and Biostatistics, 1275 York Avenue New York, NY 10065 USA

<sup>e</sup>Memorial Sloan-Kettering Cancer Center, Department of Surgery, Urology Service, 1275 York Avenue, New York, NY 10065 USA

<sup>f</sup>Memorial Sloan-Kettering Cancer Center, Department of Radiology, 1275 York Ave New York, NY 10065, USA

### Abstract

**Purpose:** To investigate associations between imaging features of tumors and age, gender and body mass index (BMI) in patients with renal cell carcinoma.

**Method:** This IRB-approved, HIPAA-compliant study included 1348 patients with histopathologically confirmed renal cell carcinoma of the clear cell subtype (ccRCC,  $n = 904$ ) or non-clear cell subtype ( $n = 444$ ), who underwent pre-treatment CT imaging less than 180 days before nephrectomy between 1999 and 2011. Two radiologists independently, retrospectively analyzed all imaging studies and identified features (necrosis, renal vein invasion, contact with

---

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\*Corresponding author. Andreas.Hoetker@usz.ch (A.M. Hötter).

Contribution author(s)

Study concepts: Hötter, Hricak, Akin, Russo.

Study design: Hötter, Hricak, Akin.

Data acquisition: Hötter, Karlo, Di Paolo.

Quality control of data and algorithms: Hötter, Karlo, Akin.

Data analysis and interpretation: Hötter, Zheng, Moskowitz.

Statistical analysis: Zheng, Moskowitz.

Manuscript preparation: all authors.

Manuscript editing: all authors.

Manuscript review: all authors.

Declaration of Competing Interest

No.

Ethical approval for research

Yes.

renal sinus fat, multicystic appearance and nodular enhancement), which were then correlated with patient age, gender and BMI at time of surgery.

**Results:** Inter-reader agreement on imaging features ranged from substantial to excellent (kappa: 0.688 to 0.982). In the ccRCC group, multicystic tumor appearance was significantly associated with lower patient age ( $p < 0.05$ ) and lower BMI ( $p < 0.05$ ); the presence of renal vein invasion was significantly associated with lower BMI in males ( $p < 0.05$ ); and both tumor contact with the renal sinus and nodular enhancement were significantly associated with greater patient age ( $p < 0.05$ ). In the non-clear cell RCC group, necrosis was associated with lower BMI for females ( $p < 0.05$ ).

**Conclusions:** This study demonstrated significant associations between imaging features of RCC and patient age and BMI, hinting an influence of these factors on tumor biology and genomic make-up. These findings could aid future studies in selecting patients while investigating genomic, molecular and metabolic variables in RCC and might potentially impact on future stratification and therapy of patients.

### Keywords

Renal cell carcinoma; Risk factors; Diagnostic imaging; CT

---

## 1. Introduction

Several risk factors have been identified that are potentially responsible for the increasing number of newly-diagnosed renal cell carcinomas [1], among them smoking [2], hypertension [3], age [4], male gender [5] and, especially with regard to the clear cell histopathologic subtype, obesity [6–10]. Though an elevated BMI is considered a major risk factor for the development of kidney cancer and is thought to be the cause of up to 27–40% of all RCCs in the United States [11,12], several independent reports have indicated that outcomes are better in obese patients than in patients of normal weight [13–16]. However, recent studies [17,18] indicate that the protective effect of obesity extended only to men and not to women. The causes of the paradoxical nature of obesity as both a risk factor and a protective characteristic in men are still unknown but may lie in the genomic make-up of the tumor [19,9].

This underscores that even within individual RCC subtypes, prognosis and clinical behavior vary strongly, and imaging features are similarly diverse: Whereas some tumors show extensive necrosis, cystic components or strong peripheral enhancement, others have a rather homogeneous enhancement pattern and appear solid on imaging. To our knowledge, no studies have yet investigated whether these ‘imaging phenotypes’ are also associated with specific risk factors (i.e., age, gender and BMI) that could themselves influence tumor biology and explain the heterogeneous collection of tumor subtypes that is still subsumed as RCC as of today. The discovery of such associations is of high interest especially as some imaging features (like renal vein invasion or nodular enhancement) have already been found to be associated with specific mutations [20].

Therefore, the purpose of our study was to correlate imaging features of RCC on CT with patient age, gender and BMI and identify associations that might lead to further insights regarding the heterogeneous clinical behavior of RCC.

## 2. Materials and methods

### 2.1. Patients

This retrospective study was HIPAA compliant and was approved by our institutional review board, which waived the requirement for informed consent. Our institution's radiology and urology databases were searched for the years 1999 through 2011 to identify all patients in whom a histopathologically proven RCC had been resected and who had undergone contrast-enhanced CT imaging of the abdomen that included at least a nephrographic phase less than 180 days before surgery. The search yielded a total of 1348 patients. The patient characteristics (age and BMI at time of surgery, gender, RCC subtype and Fuhrman grade in clear cell RCC) were retrieved from our institution's electronic medical records system.

### 2.2. Imaging

Of the 1348 CT imaging examinations included in this study, 980 (73%) were performed at our institution and 368 (27%) were performed elsewhere. The mean time interval between CT examination and surgery was 42 days (range: 0–169 days).

All imaging studies were evaluated independently by two radiologists (CAK and PLDP, blinded for review) with fellowship- and resident-level experience in the interpretation of genitourinary imaging, respectively, on commercial PACS software (Centricity, GE Healthcare, Waukesha, WI, USA). Both readers were partaking in a dedicated program for genitourinary research and had each read > 300 CT examinations of renal cell carcinoma previously. To facilitate consistent interpretation, both readers underwent training, in which they evaluated a set of cases ( $n = 90$ ) not included in the patient cohort. The readers were blinded to all clinical, histopathological and epidemiological data.

The readers assessed the presence or absence of the following imaging features: intratumoral necrosis (defined as a non-enhancing tumor region on nephrographic and/or delayed phases), gross renal vein invasion by the tumor, direct contact of the tumor with the renal sinus fat, multicystic (as opposed to solid) appearance and nodular (as opposed to homogeneous) tumor enhancement (see Fig. 1a–c for examples of these features). The selection of these imaging features before the start of the readings was based on their prior use in the literature [20] and their ability to be easily assessed on routine imaging, so that a reliable assessment could be expected. In addition, reader 1 measured the longest tumor diameter in the axial plane.

### 2.3. Statistical methods

Mean and standard deviation (SD) for age and BMI, and percentages for gender, grade and imaging features were summarized separately for patients with clear cell RCC and those with other malignant RCCs.

Agreement between the two readers was assessed using the kappa statistic, which was interpreted as proposed by Landis and Koch [21].

We first examined associations between clinical characteristics and imaging features by using (1) the Chi-squared test to examine the associations between gender and Fuhrman grade and between gender and imaging features; (2) linear regression to examine the association between age and BMI (which was approximately normally distributed in our study population, with a mean of 29.9 kg/m<sup>2</sup> and a median of 28.9 kg/m<sup>2</sup>); and (3) the t-test to compare age as well as BMI between patients with and without specific imaging features. To further examine if each imaging feature was independently associated with BMI in patients with clear cell RCC, we performed linear regression controlling for age and Fuhrman grade and applied a likelihood ratio test. In patients with non-clear cell RCC, similar tests controlling for age were applied. Associations between imaging features and BMI were also assessed separately in males and females. No adjustment for multiple testing was made, given the hypothesis-generating purpose of the study.

A test with a p-value < 0.05 was considered statistically significant. All statistical analysis was performed in SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

### 3. Results

#### 3.1. Patient and tumor characteristics

Of the 1348 patients included in the study, 904 (67%) patients (mean age 59.8 years; 316 [35%] female and 588 [65%] male) had clear cell RCC and 444 (33%) patients (mean age 60.5 years; 161 [36%] female and 283 [64%] male) had non-clear cell RCC. Of the patients with non-clear cell RCC, 167 (38%) had chromophobe RCC, 201 (45%) had papillary RCC, and 76 (17%) had unclassified RCC. Additional patient and tumor characteristics are listed in Tables 1 and 2.

Among patients with clear cell RCC, females had a significantly higher mean BMI than males (31.1 kg/m<sup>2</sup> vs 30.0 kg/m<sup>2</sup>;  $p = 0.0221$ ; Table 2), and BMI was significantly associated with age for males but not for females ( $p = 0.0318$ ; females:  $p = 0.6476$ ; both genders:  $p = 0.0988$ ).

Fuhrman grade was also distributed unequally: Females tended to have lower-grade tumors (mostly Fuhrman grade 2) compared to male patients, a majority of whom had tumors of grade 2 or 3; this trend was statistically significant ( $p < 0.001$ , Table 2). Male patients with clear cell RCC also tended to be slightly younger than female patients ( $p = 0.0166$ , Table 2).

Tumor size did not differ significantly between genders (Table 2) for patients with clear cell RCC or those with non-clear cell RCC, and there was no difference in age or BMI between female and male patients in the non-clear cell RCC group. However, a significant association between BMI and age was found for all patients with non-clear cell RCC ( $p = 0.009$ ); when the patients were stratified by gender, this association was only significant for males (females:  $p = 0.1205$ ; males:  $p = 0.0298$ ).

### 3.2. Inter-reader agreement

Inter-reader agreement on imaging features was mostly excellent ( $\kappa$ : 0.934–0.980 in clear cell RCC, 0.863–0.982 in non-clear cell RCC), except with regard to renal vein invasion, regarding which agreement was substantial ( $\kappa$ : 0.688 in clear cell RCC and 0.694 in non-clear cell RCC).

### 3.3. Associations between imaging features and age, gender and BMI

Detailed results regarding associations between imaging features and patient characteristics can be found in Table 3a (clear cell RCC) and Table 3b (non-clear cell RCC).

In the clear cell RCC group, patients with tumors of multicystic appearance were significantly younger (57.2/57.4 vs 60.2/60.1 years;  $p = 0.0084$  and  $p = 0.0149$ , for the two readers) and also had significantly lower BMI (28.7/28.9 kg/m<sup>2</sup> vs 30.8/30.7 kg/m<sup>2</sup>;  $p < 0.0001$  and  $p = 0.0007$ ) than those with solid tumors. These associations remained statistically significant for both males and females with clear cell RCC when adjusting for Fuhrman grade and age and including gender as an additional distinction. An association between multicystic tumor appearance and lower BMI was also found in the non-clear cell RCC group, but it did not remain statistically significant after adjusting for age (except for reader 2 when looking at both genders, Table 3b).

Renal vein invasion was associated with significantly lower BMI in males with clear cell RCC (28.7/28.0 kg/m<sup>2</sup> vs 30.2/30.2 kg/m<sup>2</sup>,  $p = 0.0441$  and  $0.0067$ ); this association was not seen in females with clear cell RCC or in patients with non-clear cell RCC. In addition, nodular enhancement (60.5/60.5 vs 58.3/58.3 years;  $p = 0.0068$  and  $p = 0.0069$ ) and contact between the tumor and the renal sinus fat (60.4/60.3 vs 57.3/57.3 years;  $p = 0.002$  and  $0.0026$ ) were significantly associated with greater age in the group of patients with clear cell RCC.

In the non-clear cell RCC group, a higher rate of necrosis was associated with a lower BMI (28.0/27.9 vs 29.6/29.6 kg/m<sup>2</sup>;  $p = 0.0047$  and  $p = 0.0029$ , Table 3b), but after adjusting for age, this association only remained statistically significant for females ( $p = 0.0328$  and  $p = 0.0184$ ).

## 4. Discussion

Age, gender and BMI are long-established risk factors for cancer development that influence cancer-specific morbidity and mortality, and their influence extends to renal cancer [8,22]. Though obesity in particular is known to significantly increase the risk of developing clear cell RCC [6–8,11,12], several independent groups have shown that patients with clear cell RCC who have a higher BMI paradoxically have a better prognosis than those of normal weight [23,14,15]. This “obesity paradox” was most recently described in two studies [17,18], which found that the benefits of an elevated BMI were restricted to the male study population.

While the underlying causes of the obesity paradox are still unknown, the results of these recent studies add to the mounting evidence that even a histopathological subtype such

as clear cell RCC does not represent a single entity [24,19,25], but rather constitutes a heterogeneous family of tumors with varying levels of aggressiveness and differing genomic, molecular and metabolic characteristics that are affected by epidemiological factors. For example, there is growing evidence that the expression of certain genes in the fatty acid metabolism of clear cell RCC is influenced by epidemiological factors, especially by obesity [19]. Ongoing research is therefore focused on further exploring the genomic, molecular, metabolic and epidemiologic variables that could potentially explain the observed clinical heterogeneity in RCC. However, the heterogeneity of the imaging features of RCC has not yet been incorporated into these investigations. Given the established associations between imaging features of RCC and certain mutations [20], we aimed to investigate potential associations between distinctive imaging features and patient age, gender and BMI.

One of our most interesting findings was that a multicystic tumor appearance was significantly associated with younger age as well as lower BMI in patients (both men and women) with clear cell RCC. This is of importance, as it has recently been demonstrated that in clear cell RCCs of multicystic appearance, mutations of SETD2, KDM5C and BAP1 are not seen and mutations of VHL and PBRM1 are significantly less common than in solid clear cell RCCs [20]. A fraction of these multicystic tumors might represent multilocular cystic clear cell RCC of low malignant potential, a rare entity and low-grade subtype of clear cell RCC with a favorable prognosis [26,27]; such a circumstance would align well with findings linking the mutations mentioned above with poor outcome in patients with solid tumors [19,28]. However, the association between a multicystic tumor appearance and lower BMI also reached statistical significance in the non-clear cell RCC group, though only for one reader after adjusting for age, and not when patients were differentiated by gender. The reasons for the findings in this group require further investigation in a larger cohort of patients with non-clear cell RCC who could be stratified by histological subtype. In perspective, molecular alterations specific for an individual imaging phenotype might even allow for the personalization of therapies based on CT imaging.

Our finding that renal vein invasion, which is a known sign of poor prognosis [29], was significantly associated with a lower BMI in males with clear cell RCC might provide an explanation for the so-called “protective effect” of a higher BMI [13,14] in males [17,18]. The fact that this association remained statistically significant even after adjusting for age and Fuhrman grade suggests the presence of a distinct and more aggressive subtype in these patients, influenced by epidemiological features. Interestingly, the association between renal vein invasion and lower BMI might be unique to clear cell RCC, as it was not found in the patients with non-clear cell RCC. In this context, the differentiation between visceral and retroperitoneal fat could be of interest in future studies, as recent investigations indicate a distinct influence of the fat distribution on survival in patients with RCC [30].

The fact that patients with clear cell RCC whose tumors were in direct contact with the renal sinus fat were slightly but significantly older might also reflect the presence of a more aggressive tumor type in older patients. However, the differences between the patient groups assessed in this comparison were small in absolute numbers, which limits the applicability of this finding to routine clinical care. Nodular contrast enhancement, which was also associated with greater age in patients with clear cell RCC in our analysis, has been found to

be associated with a mutation of the VHL gene in clear cell RCC [20]. Thus, taken together, these findings align well with prior findings of a higher rate of VHL mutations in older patients [31].

The presence of necrosis at histopathology is another established poor prognostic factor [32]. Although microscopic necrosis is not evident on clinical imaging, gross necrosis can be appreciated on contrast-enhanced CT as a non-enhancing area of tumor. In our study, necrosis on CT was associated with significantly lower BMI in females with non-clear cell RCC though not in males with non-clear cell RCC after adjusting for age. The molecular reasons for this association are unknown and might represent a motif for future studies.

In our study, we were not able to correlate certain entities (e.g., a multicystic tumor appearance on imaging and an actual histopathological diagnosis of multilocular cystic RCC) due to the long patient inclusion period of 12 years and the fact that the international histopathological classification of renal cell carcinoma was revised during this period. Even though our study population as a whole was large, the low number of patients with less common RCC subtypes forced us to analyze the data for all patients with non-clear cell RCC as a group and not stratified by RCC subtype. Also, our investigation was designed as an exploratory study to find correlations between imaging features and epidemiological factors only, and it did not include genomic or detailed histopathological assessment of the tumor specimens. As such, the interpretation of our findings is complicated by the fact that the exact biochemical/genomic pathways for the influence of epidemiological factors we were able to demonstrate are still unknown. Further studies will be needed to investigate the exact molecular causes, possibly in relation to other known epidemiological risk factors. In addition, due to the hypothesis-generating purpose of this study, we did not perform adjustment for multiple testing and therefore our results require verification in a separate cohort.

Finally, though the interval between CT examination and surgery was relatively short (averaging 42 days), it was not possible to account for potential changes in patients' BMI during that interval. Additionally, we required all CT examinations to include an intravenous contrast agent, which greatly increases image quality and helps in the assessment of qualitative imaging features. As a result of this decision, patients with renal impairment, in whom the injection of an intravenous contrast agent would have been contra-indicated, could not be included into our study.

In conclusion, this study identified associations of imaging features with age and BMI in patients with RCC that are known to affect outcome and therefore suggest the existence of additional subtypes of RCC with differing levels of aggressiveness and prognoses, influenced by these epidemiological factors. These findings could potentially impact on future stratification and therapy of patients, maybe even allowing personalization of therapies based on imaging features. Future genomic, molecular and metabolic studies of RCC that incorporate our findings – for example, by including subset analyses of solid vs cystic tumors or of tumors from male patients with clear cell RCC and lower BMI – might provide new insights into the causes of the heterogeneous clinical appearance and behavior of RCC.



## Acknowledgments

### Funding information

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30CA008748.

### External funding

Yes.

### Source of funding

NIH.

## References

- [1]. Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, et al., Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis, *Eur. Urol.* 59 (2011) 135–141, 10.1016/j.eururo.2010.10.029. [PubMed: 21035250]
- [2]. Tsivian M, Moreira DM, Caso JR, Mouraviev V, Polascik TJ, Cigarette smoking is associated with advanced renal cell carcinoma, *J. Clin. Oncol.* 29 (2011) 2027–2031, 10.1200/JCO.2010.30.9484. [PubMed: 21502558]
- [3]. Colt JS, Schwartz K, Graubard BI, Davis F, Ruterbusch J, DiGaetano R, et al., Hypertension and risk of renal cell carcinoma among white and black Americans, *Epidemiology* 22 (2011) 797–804, 10.1097/EDE.0b013e3182300720. [PubMed: 21881515]
- [4]. Hew MN, Zonneveld R, Intan PED, Kümmerlin D, Opondo JMCH, Jean de la Rosette, Laguna MP, Age and gender related differences in renal cell carcinoma in a European cohort, *J. Urol.* 188 (2012) 33–38, 10.1016/j.juro.2012.02.2573. [PubMed: 22578731]
- [5]. Aron M, Nguyen MM, Stein RJ, Gill IS, Impact of gender in renal cell carcinoma: an analysis of the SEER database, *Eur. Urol.* 54 (2008) 133–140, 10.1016/j.eururo.2007.12.001. [PubMed: 18160207]
- [6]. Purdue MP, Moore LE, Merino MJ, Boffetta P, Colt JS, Schwartz KL, et al., An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies, *Int. J. Cancer* 132 (2013) 2640–2647, 10.1002/ijc.27934. [PubMed: 23150424]
- [7]. Beebe-Dimmer JL, Colt JS, Ruterbusch JJ, Keele GR, Purdue MP, Wacholder S, et al., Body mass index and renal cell cancer, *Epidemiology* 23 (2012) 821–828, 10.1097/EDE.0b013e31826b7fe9. [PubMed: 23007040]
- [8]. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, *Lancet* 371 (2008) 569–578, 10.1016/S0140-6736(08)60269-X. [PubMed: 18280327]
- [9]. Sanchez A, Furberg H, Kuo F, Vuong L, Ged Y, Patil S, et al., Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study, *Lancet Oncol.* 21 (2020) 283–293, 10.1016/S1470-2045(19)30797-1. [PubMed: 31870811]
- [10]. Callahan CL, Hofmann JN, Corley DA, Zhao WK, Shuch B, Chow W-H, Purdue MP, Obesity and renal cell carcinoma risk by histologic subtype: a nested case-control study and meta-analysis, *Cancer Epidemiol.* 56 (2018) 31–37, 10.1016/j.canep.2018.07.002. [PubMed: 30029068]
- [11]. Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A, Obesity and renal cell cancer—a quantitative review, *Br. J. Cancer* 85 (2001) 984–990, 10.1038/sj.bjc.6692040. [PubMed: 11592770]
- [12]. Calle EE, Kaaks R, Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms, *Nat. Rev. Cancer* 4 (2004) 579–591, 10.1038/nrc1408. [PubMed: 15286738]
- [13]. Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, et al., Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis, *Int. J. Cancer* 132 (2013) 625–634, 10.1002/ijc.27639. [PubMed: 22610826]



- [14]. Steffens S, Ringe KI, Schroerer K, Lehmann R, Rustemeier J, Wegener G, et al., Does overweight influence the prognosis of renal cell carcinoma? Results of a multicenter study, *Int. J. Urol.* 20 (2013) 585–592, 10.1111/iju.12000. [PubMed: 23176631]
- [15]. Sunela KL, Kataja MJ, Kellokumpu-Lehtinen P-LI, Influence of body mass index and smoking on the long-term survival of patients with renal cell Cancer, *Clin. Genitourin. Cancer* (2013) 458–464. [PubMed: 23810440]
- [16]. Mano R, Hakimi AA, Zabor EC, Bury MA, Donati OF, Karlo CA, et al., Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma, *Can. Urol. Assoc. J.* 8 (2014) 80, 10.5489/cuaj.1979.
- [17]. Ohno Y, Nakashima J, Nakagami Y, Satake N, Gondo T, Ohori M, et al., Sex and the clinical value of body mass index in patients with clear cell renal cell carcinoma, *Br. J. Cancer* 109 (2013) 1899–1903, 10.1038/bjc.2013.512. [PubMed: 24002606]
- [18]. Zheng Y, Bao L, Chen J, Pan Y, Wang Q, Chen L, Gao X, The influence of sex on the prognostic value of body mass index in non-metastasis renal cell carcinoma, *Cancer Manag. Res.* 11 (2019) 3869–3886, 10.2147/CMAR.S197457. [PubMed: 31118803]
- [19]. Hakimi AA, Furberg H, Zabor EC, Jacobsen A, Schultz N, Ciriello G, et al., An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma, *J. Natl. Cancer Inst.* 105 (2013) 1862–1870, 10.1093/jnci/djt310. [PubMed: 24285872]
- [20]. Karlo CA, Di Paolo, Luigi Pier, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, et al., Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations, *Radiology* 270 (2014) 464–471, 10.1148/radiol.13130663. [PubMed: 24029645]
- [21]. Landis JR, Koch GG, The measurement of observer agreement for categorical data, *Biometrics* (1977) 159–174. [PubMed: 843571]
- [22]. Chow W-H, Dong LM, Devesa SS, Epidemiology and risk factors for kidney cancer, *Nat. Rev. Urol.* 7 (2010) 245–257, 10.1038/nrurol.2010.46. [PubMed: 20448658]
- [23]. Choi Y, Park B, Kim K, Jeong BC, Seo SI, Jeon SS, et al., Erythrocyte sedimentation rate and anaemia are independent predictors of survival in patients with clear cell renal cell carcinoma, *Br. J. Cancer* 108 (2013) 387–394, 10.1038/bjc.2012.565. [PubMed: 23299540]
- [24]. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al., Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing, *Nat. Genet.* 46 (2014) 225–233, 10.1038/ng.2891. [PubMed: 24487277]
- [25]. Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Gordon Robertson A, et al., Comprehensive molecular characterization of clear cell renal cell carcinoma, *Nature* 499 (2013) 43–49, 10.1038/nature12222. [PubMed: 23792563]
- [26]. Huber J, Winkler A, Jakobi H, Bruckner T, Roth W, Hallscheidt P, et al., Preoperative decision making for renal cell carcinoma: cystic morphology in cross-sectional imaging might predict lower malignant potential, *Urol. Oncol.* 32 (2014) 37, 10.1016/j.urolonc.2013.02.016.
- [27]. Halat S, Eble JN, Grignon DJ, Lopez-Beltran A, Montironi R, Tan P-H, et al., Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma, *Mod. Pathol.* 23 (2010) 931–936, 10.1038/modpathol.2010.78. [PubMed: 20348877]
- [28]. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, et al., Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation, *Lancet Oncol.* 14 (2013) 159–167, 10.1016/S1470-2045(12)70584-3. [PubMed: 23333114]
- [29]. Ljungberg B, Stenling R, Osterdahl B, Farrelly E, Aberg T, Roos G, Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival, *J. Urol.* 154 (1995) 1681–1684. [PubMed: 7563321]
- [30]. Nguyen GK, Mellnick VM, Yim AK-Y, Salter A, Ippolito JE, Synergy of sex differences in visceral fat measured with CT and tumor metabolism helps predict overall survival in patients with renal cell carcinoma, *Radiology* 287 (2018) 884–892, 10.1148/radiol.2018171504. [PubMed: 29558292]
- [31]. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, et al., VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma, *J. Natl. Cancer Inst.* 94 (2002) 1569–1575. [PubMed: 12381710]


- [32]. Park I, Cho YM, Lee J-L, Ahn J-H, Lee J-L, Song C, et al., Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component, *J. Cancer Res. Clin. Oncol.* 139 (2013) 817–827, 10.1007/s00432-013-1386-4. [PubMed: 23397357]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Fig. 1.** (a–c) Examples of imaging features measured on CT. (a) Large, centrally necrotic clear cell RCC, demonstrating contact with the renal sinus fat and nodular enhancement; (b) clear cell RCC in the right kidney with renal vein invasion; and (c) multicystic tumor appearance.

**Table 1**Patient characteristics for clear cell RCC ( $n = 904$ ) and non-clear cell RCC ( $n = 444$ ) groups.

<b>Gender</b>	<b>Clear cell RCC N (%)</b>	<b>Non-clear cell RCC N (%)</b>
F	316 (35%)	161 (36%)
M	588 (65%)	283 (64%)
<b>T stage *</b>		
T1a	449 (49.7%)	227 (51.1%)
T1b	137 (15.2%)	84 (18.9%)
T2a	29 (3.2%)	22 (5.0%)
T2b	10 (1.1%)	18 (4.1%)
T3a	94 (10.4%)	61 (13.7%)
T3b	174 (19.2%)	32 (7.2%)
T3c	2 (0.2%)	0 (0%)
T4	9 (1.0%)	0 (0%)
<b>N stage *</b>		
N-	282 (31.2%)	77 (17.3%)
N+	14 (1.5%)	22 (5%)
Nx	608 (67.3%)	345 (77.7%)
<b>M stage *</b>		
M-	827 (91.5%)	430 (96.8%)
M+	77 (8.5%)	14 (3.2%)

\* as indicated by histopathological report.

**Table 2**

Comparison of BMI (kg/m<sup>2</sup>), Fuhrman grade (only applicable in clear cell RCC), age (years) and tumor size on CT (cm) between genders for patients with clear cell RCC and non-clear cell RCC.

Clear cell RCC				
	Both genders	Female	Male	<i>p</i> -value *
BMI, mean (SD) Fuhrman grade	30.4 (6.4)	31.1 (7.5)	30.0 (5.8)	0.0221
1, <i>n</i> (%)	25 (3%)	8 (3%)	17 (3%)	< .001
2, <i>n</i> (%)	449 (50%)	202 (64%)	247 (42%)	
3, <i>n</i> (%)	363 (40%)	86 (27%)	277 (47%)	
4, <i>n</i> (%)	66 (7%)	19 (6%)	47 (8%)	
Age, mean (SD)	59.8 (11.9)	61.0 (12.1)	59.0 (11.6)	0.0166
Tumor size (cm), mean (SD)	4.8 (2.8)	4.6 (2.9)	4.9 (2.8)	0.1305
Non-clear cell RCC				
	Both genders	Female	Male	<i>p</i> -value *
BMI, mean (SD)	28.9 (5.5)	28.7 (6.8)	29.0 (4.7)	0.7087
Age, mean (SD)	60.5 (11.3)	60 (12)	61 (12)	0.3483
Tumor size (cm), mean (SD)	4.4 (3.0)	4.2 (3.0)	4.6 (3.0)	0.1674

\* *p*-value for the comparison between male and female patients.

**Table 3a**

Association between patient characteristics and CT features in clear cell RCC (BMI: kg/m<sup>2</sup>, age: years, R1 = reader 1, R2 = reader 2).

CT Features	Age		Gender		BMI			BMI in females			BMI in Males		
	Mean (SD)	p-value	Female	Male	Mean (SD)	p-value	Adjusted p-value*	Mean (SD)	p-value	Adjusted p-value*	Mean (SD)	p-value	Adjusted p-value*
Necrosis (R1)	No	0.1792	38 (12%)	76 (13%)	31.0 (7.3)	0.3271	0.3412	31.3 (8.7)	0.8841	0.9569	30.9 (6.5)	0.2133	0.2390
	Yes		278 (88%)	512 (87%)	30.3 (6.3)			31.1 (7.3)			29.9 (5.6)		
Necrosis (R2)	No	0.2177	39 (12%)	79 (13%)	30.9 (7.2)	0.3961	0.4263	31.2 (8.6)	0.9681	0.9491	30.8 (6.4)	0.2423	0.2798
	Yes		277 (88%)	509 (87%)	30.3 (6.3)			31.1 (7.3)			29.9 (5.6)		
Renal vein invasion (R1)	No	0.3657	275 (87%)	505 (86%)	30.5 (6.4)	0.0649	0.1924	31.2 (7.4)	0.8068	0.7962	30.2 (5.8)	<b>0.0190</b>	<b>0.0441</b>
	Yes		41 (13%)	83 (14%)	29.4 (6.3)			30.8 (7.9)			28.7 (5.3)		
Renal vein invasion (R2)	No	0.9160	288 (91%)	523 (89%)	30.5 (6.5)	0.0203	0.1108	31.1 (7.5)	0.8764	0.3636	30.2 (5.8)	<b>0.0012</b>	<b>0.0067</b>
	Yes		28 (9%)	65 (11%)	29.0 (5.8)			31.3 (7.1)			28.0 (4.9)		
Contact renal sinus fat (R1)	No	<b>0.0020</b>	75 (24%)	130 (22%)	30.3 (5.8)	0.7213	0.2857	29.9 (5.9)	0.0663	0.0521	30.5 (5.7)	0.3033	0.6348
	Yes		241 (76%)	458 (78%)	30.4 (6.6)			31.5 (7.9)			29.9 (5.8)		
Contact renal sinus fat (R2)	No	<b>0.0026</b>	71 (22%)	124 (21%)	30.3 (5.8)	0.8926	0.4035	30.1 (6.0)	0.1195	0.0909	30.5 (5.7)	0.2801	0.5729
	Yes		245 (78%)	464 (79%)	30.4 (6.6)			31.4 (7.8)			29.9 (5.8)		
Multicystic (R1)	No	<b>0.0084</b>	258 (82%)	478 (81%)	30.8 (6.6)	<.0001	<.0001	31.7 (7.6)	<b>0.0011</b>	<b>0.0027</b>	30.3 (6.0)	<b>0.0035</b>	<b>0.0060</b>
	Yes		58 (18%)	110 (19%)	28.7 (5.2)			28.5 (6.2)			28.8 (4.6)		
Multicystic (R2)	No	<b>0.0149</b>	263 (83%)	490 (83%)	30.7 (6.6)	<b>0.0002</b>	<b>0.0007</b>	31.6 (7.7)	<b>0.0070</b>	<b>0.0169</b>	30.2 (5.9)	<b>0.0115</b>	<b>0.0180</b>
	Yes		53 (17%)	98 (17%)	28.9 (5.2)			28.9 (6.1)			28.9 (4.6)		
Nodular enhancement (R1)	No	<b>0.0068</b>	107 (34%)	227 (39%)	30.6 (6.5)	0.4003	0.5315	31.8 (8.1)	0.2846	0.3304	30.1 (5.5)	0.7763	0.9290

CT Features	Age		Gender		BMI		BMI in females			BMI in Males			
	Mean (SD)	p-value	Female	Male	Mean (SD)	p-value	Adjusted p-value*	Mean (SD)	p-value	Adjusted p-value*	Mean (SD)	p-value	Adjusted p-value*
	60.5 (11.7)		209 (66%)	361 (61%)	30.3 (6.4)			30.8 (7.1)			29.9 (5.9)		
Nodular enhancement (R2)	58.3 (12.0)	<b>0.0069</b>	112 (35%)	246 (42%)	30.5 (6.4)	0.0609	0.8963	31.7 (8.0)	0.3446	0.4116	30.0 (5.4)	0.8732	0.7034
	60.5 (11.6)		204 (65%)	342 (58%)	30.3 (6.5)			30.8 (7.2)			30.0 (6.0)		

\* p-value adjusted for Fuhrman grade and age.



Table 3b

Association between patient characteristics and CT features in non-clear cell RCC (BMI: kg/m<sup>2</sup>, age: years, R1 = reader 1, R2 = reader 2).

CT features	Age		Gender		BMI			BMI in females			BMI in Males		
	Mean (SD)	p-value	Female	Male	Mean (SD)	p-value	Adjusted p-value*	Mean (SD)	p-value	Adjusted p-value*	Mean (SD)	p-value	Adjusted p-value*
Necrosis (R1)	No	0.0563	89 (55%)	166 (59%)	29.6 (5.7)	0.0021	0.0047	29.8 (7.3)	0.0226	0.0328	29.4 (4.7)	0.0431	0.0669
	Yes		72 (45%)	117 (41%)	28.0 (5.1)			27.4 (6.0)			28.3 (4.5)		
Necrosis (R2)	No	0.1602	90 (56%)	167 (59%)	29.6 (5.7)	0.0015	0.0029	29.9 (7.2)	0.0148	0.0184	29.4 (4.7)	0.0467	0.0683
	Yes		71 (44%)	116 (41%)	27.9 (5.2)			27.3 (6.1)			28.3 (4.6)		
Renal vein invasion (R1)	No	0.8025	155 (96%)	272 (96%)	28.9 (5.6)	0.778	0.8126	28.8 (6.9)	0.3902	0.4909	28.9 (4.7)	0.7098	0.6955
	Yes		6 (4%)	11 (4%)	28.5 (5.0)			26.7 (5.3)			29.5 (4.9)		
Renal vein invasion (R2)	No	0.7983	156 (97%)	271 (96%)	28.8 (5.5)	0.3122	0.2386	28.7 (6.8)	0.4904	0.4447	28.9 (4.6)	0.4957	0.3527
	Yes		5 (3%)	12 (4%)	30.4 (6.1)			30.8 (6.3)			30.2 (6.3)		
Contact renal sinus fat (R1)	No	0.0769	60 (37%)	117 (41%)	28.8 (5.0)	0.815	0.9915	28.7 (6.4)	0.9141	0.8891	28.9 (4.2)	0.8016	0.8619
	Yes		101 (63%)	166 (59%)	28.9 (5.9)			28.8 (7.1)			29.0 (5.0)		
Contact renal sinus fat (R2)	No	0.0821	62 (39%)	119 (42%)	28.9 (5.0)	0.9557	0.7868	28.9 (6.4)	0.7798	0.5842	28.9 (4.2)	0.8074	0.8515
	Yes		99 (61%)	164 (58%)	28.9 (5.9)			28.6 (7.1)			29.0 (5.0)		
Multicystic (R1)	No	0.3529	151 (94%)	267 (94%)	29.0 (5.6)	0.0057	0.0582	28.9 (7.0)	0.0016	0.1988	29.1 (4.7)	0.1242	0.1669
	Yes		10 (6%)	16 (6%)	26.8 (3.5)			26.0 (1.9)			27.3 (4.3)		
Multicystic (R2)	No	0.5782	153 (95%)	271 (96%)	29.0 (5.6)	0.0001	0.0260	28.9 (6.9)	0.0056	0.2217	29.1 (4.7)	0.0092	0.0508
	Yes		8 (5%)	12 (4%)	26.3 (2.5)			26.1 (2.0)			26.4 (2.9)		
Nodular enhancement (R1)	No	0.5654	124 (77%)	230 (81%)	29.1 (5.4)	0.2212	0.2195	29.1 (6.7)	0.2748	0.3363	29.0 (4.6)	0.5711	0.4956
	Yes		37 (23%)	53 (19%)	28.2 (5.9)			27.6 (7.2)			28.6 (4.9)		

CT features	Age		Gender		BMI		BMI in females			BMI in Males			
	Mean (SD)	p-value	Female	Male	Mean (SD)	p-value	Adjusted p-value*	Mean (SD)	p-value	Adjusted p-value*	Mean (SD)	p-value	Adjusted p-value*
Nodular enhancement (R2)	No	0.3622	126 (78%)	232 (82%)	29.1 (5.4)	0.1715	0.1767	29.1 (6.7)	0.2250	0.2673	29.1 (4.6)	0.5156	0.4796
	Yes	61.4 (11.5)	35 (22%)	51 (18%)	28.1 (5.9)			27.4 (7.2)			28.6 (5.0)		

\* p-value adjusted for age.